{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:33:28Z","timestamp":1793046808899,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale<\/jats:title>\n            <jats:p>Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience again.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study used the data of 151 healthy volunteers who had ingested serotonergic psychedelics in one of six randomized, double-blind, placebo-controlled crossover trials at the same research site under similar conditions. The data were analyzed through qualitative content analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The predominant motivations to participate in a trial were interest in psychedelics and an appealing setting. Expectations involved personal development and the occurrence of typical psychedelic effects. Hopes included transformative processes. The setting factors that promoted a positive experience were music and access to nature, whereas the sterile hospital environment was considered bothersome. Most participants valued the trusting relationship with their investigator. The most commonly criticized investigator characteristics were a perceived lack of support and investigator-induced psychological discomfort. Most participants considered their expectations exceeded and would take the study substances again, preferably in a setting in nature with friends.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This paper identified four pivotal factors to be considered for psychedelic study experiences: (1) a secure interpersonal relationship, (2) an aesthetically pleasing environment, (3) access to nature, and (4) the use of music. This analysis reveals subjective views of volunteers in psychedelic Phase-I trials and may improve research standards.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00213-025-06772-4","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:54:41Z","timestamp":1743281681000},"page":"1875-1892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers"],"prefix":"10.1007","volume":"242","author":[{"given":"Laura","family":"Ley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Straumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Klaiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin B.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Arikci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-584X","authenticated-orcid":false,"given":"Yasmin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"6","key":"6772_CR1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","volume":"239","author":"JS Aday","year":"2022","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD (2022) Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology 239(6):1989\u20132010. https:\/\/doi.org\/10.1007\/s00213-022-06123-7","journal-title":"Psychopharmacology"},{"issue":"6","key":"6772_CR2","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/dar.13480","volume":"41","author":"LA Basedow","year":"2022","unstructured":"Basedow LA, Kuitunen-Paul S (2022) Motives for the use of serotonergic psychedelics: a systematic review. Drug Alcohol Rev 41(6):1391\u20131403. https:\/\/doi.org\/10.1111\/dar.13480","journal-title":"Drug Alcohol Rev"},{"key":"6772_CR3","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","volume":"13","author":"GJ Bathje","year":"2022","unstructured":"Bathje GJ, Majeski E, Kudowor M (2022) Psychedelic integration: an analysis of the concept and its practice. Front Psychol 13:824077. https:\/\/doi.org\/10.3389\/fpsyg.2022.824077","journal-title":"Front Psychol"},{"issue":"2","key":"6772_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","volume":"26","author":"AM Becker","year":"2023","unstructured":"Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, Eckert A, Liechti ME (2023) Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychop 26(2):97\u2013106. https:\/\/doi.org\/10.1093\/ijnp\/pyac075","journal-title":"Int J Neuropsychop"},{"issue":"4","key":"6772_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1177\/0022167817706884","volume":"57","author":"AB Belser","year":"2017","unstructured":"Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman HL, Guss J, Bossis A, Ross S (2017) Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J Humanist Psychol 57(4):354\u2013388. https:\/\/doi.org\/10.1177\/0022167817706884","journal-title":"J Humanist Psychol"},{"issue":"2","key":"6772_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00213-023-06394-8","volume":"9","author":"HL Bonny","year":"1972","unstructured":"Bonny HL, Pahnke WN (1972) The use of music in psychedelic (LSD) psychotherapy. J Music Ther 9(2):64\u201387. https:\/\/doi.org\/10.1007\/s00213-023-06394-8","journal-title":"J Music Ther"},{"issue":"9","key":"6772_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2023.1412","volume":"80","author":"L Colloca","year":"2023","unstructured":"Colloca L, Nikayin S, Sanacora G (2023) The intricate interaction between expectations and therapeutic outcomes of psychedelic agents. JAMA Psychiat 80(9):867\u2013868. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1412","journal-title":"JAMA Psychiat"},{"issue":"1","key":"6772_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T (2015) LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 29(1):57\u201368. https:\/\/doi.org\/10.1177\/0269881114555249","journal-title":"J Psychopharmacol"},{"issue":"6","key":"6772_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, Becker AM, Straumann I, Vizeli P, Silva Kuehne S, Roder MA, Duthaler U, Kolaczynska KE, Varghese N, Eckert A, Liechti ME (2022) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol 47(6):1180\u20131187. https:\/\/doi.org\/10.1038\/s41386-022-01297-2","journal-title":"Neuropsychopharmacol"},{"issue":"2","key":"6772_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/psychoactives2020012","volume":"2","author":"A Irvine","year":"2023","unstructured":"Irvine A, Luke D, Harrild F, Gandy S, Watts R (2023) Transpersonal ecodelia: surveying psychedelically induced biophilia. Psychoactives 2(2):174\u2013193. https:\/\/doi.org\/10.3390\/psychoactives2020012","journal-title":"Psychoactives"},{"issue":"6","key":"6772_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620. https:\/\/doi.org\/10.1177\/0269881108093587","journal-title":"J Psychopharmacol"},{"key":"6772_CR12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00213-017-4820-5","volume":"235","author":"M Kaelen","year":"2018","unstructured":"Kaelen M, Giribaldi B, Raine J, Evans L, Timmermann C, Rodriguez N, Feilding A, Nutt D, Carhart-Harris R (2018) The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology 235:505\u2013519. https:\/\/doi.org\/10.1007\/s00213-017-4820-5","journal-title":"Psychopharmacology"},{"issue":"3","key":"6772_CR13","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/0091450919863899","volume":"46","author":"H Kettner","year":"2019","unstructured":"Kettner H, Mason NL, Kuypers KP (2019a) Motives for classical and novel psychoactive substances use in psychedelic polydrug users. Contemp Drug Probl 46(3):304\u2013320. https:\/\/doi.org\/10.1177\/0091450919863899","journal-title":"Contemp Drug Probl"},{"issue":"24","key":"6772_CR14","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.3390\/ijerph16245147","volume":"16","author":"H Kettner","year":"2019","unstructured":"Kettner H, Gandy S, Haijen ECHM, Carhart-Harris RL (2019b) From egoism to ecoism: psychedelics increase nature relatedness in a state-mediated and context-dependent manner. Int J Environ Res Public Health 16(24):5147. https:\/\/doi.org\/10.3390\/ijerph16245147","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"6772_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","volume":"14","author":"A Klaiber","year":"2024","unstructured":"Klaiber A, Schmid Y, Becker AM, Straumann I, Erne L, Jelusic A, Thomann J, Luethi D, Liechti ME (2024) Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. Transl Psychiatry 14(1):395. https:\/\/doi.org\/10.1038\/s41398-024-03116-2","journal-title":"Transl Psychiatry"},{"issue":"9","key":"6772_CR16","doi-asserted-by":"publisher","first-page":"e29167","DOI":"10.7759\/cureus.29167","volume":"14","author":"JS Kurtz","year":"2022","unstructured":"Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, Picton B, Harris M, Hatter M, Beyer R, Sahyouni R, Diaz-Aguilar LD, Castellanos J, Schuster N, Abraham ME (2022) The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American drug trial registry. Cureus 14(9):e29167. https:\/\/doi.org\/10.7759\/cureus.29167","journal-title":"Cureus"},{"issue":"5","key":"6772_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW (2017) Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs 49(5):427\u2013435. https:\/\/doi.org\/10.1080\/02791072.2017.1361559","journal-title":"J Psychoactive Drugs"},{"key":"6772_CR18","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","volume":"48","author":"L Ley","year":"2023","unstructured":"Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacol 48:1659\u20131667. https:\/\/doi.org\/10.1038\/s41386-023-01607-2","journal-title":"Neuropsychopharmacol"},{"issue":"1","key":"6772_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/02791072.2013.873157","volume":"46","author":"A Loizaga-Velder","year":"2014","unstructured":"Loizaga-Velder A, Verres R (2014) Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence: qualitative results. J Psychoactive Drugs 46(1):63\u201372. https:\/\/doi.org\/10.1080\/02791072.2013.873157","journal-title":"J Psychoactive Drugs"},{"issue":"9280","key":"6772_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0140-6736(01)05627-6","volume":"358","author":"K Malterud","year":"2001","unstructured":"Malterud K (2001) Qualitative research: standards, challenges, and guidelines. Lancet 358(9280):483\u2013488. https:\/\/doi.org\/10.1016\/S0140-6736(01)05627-6","journal-title":"Lancet"},{"key":"6772_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-658-21308-4_42","volume-title":"Qualitative inhaltsanalyse","author":"P Mayring","year":"2019","unstructured":"Mayring P, Fenzl T (2019) Qualitative inhaltsanalyse. Springer Fachmedien, Wiesbaden. https:\/\/doi.org\/10.1007\/978-3-658-21308-4_42"},{"issue":"3","key":"6772_CR22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1080\/02791072.2011.605661","volume":"43","author":"L M\u00f3r\u00f3","year":"2011","unstructured":"M\u00f3r\u00f3 L, Simon K, B\u00e1rd I, R\u00e1cz J (2011) Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users. J Psychoactive Drugs 43(3):188\u2013198. https:\/\/doi.org\/10.1080\/02791072.2011.605661","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"6772_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1089\/eco.2022.0044","volume":"15","author":"K Newton","year":"2023","unstructured":"Newton K, Moreton SG (2023) Self-transcendent positive emotions as a potential mechanism underpinning the effects of meaningful psychedelic experiences on connectedness to nature. Ecopsychology 15(2):142\u2013159. https:\/\/doi.org\/10.1089\/eco.2022.0044","journal-title":"Ecopsychology"},{"key":"6772_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fphar.2018.00132","volume":"9","author":"EM Nielson","year":"2018","unstructured":"Nielson EM, May DG, Forcehimes AA, Bogenschutz MP (2018) The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol 9:132. https:\/\/doi.org\/10.3389\/fphar.2018.00132","journal-title":"Front Pharmacol"},{"issue":"7","key":"6772_CR25","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1177\/0269881118780612","volume":"32","author":"T Noorani","year":"2018","unstructured":"Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, Johnson MW (2018) Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol 32(7):756\u2013769. https:\/\/doi.org\/10.1177\/0269881118780612","journal-title":"J Psychopharmacol"},{"issue":"13","key":"6772_CR26","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1017\/S0033291723001289","volume":"53","author":"T Noorani","year":"2023","unstructured":"Noorani T, Bedi G, Muthukumaraswamy S (2023) Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials. Psychol Med 53(13):5892\u20135901. https:\/\/doi.org\/10.1017\/S0033291723001289","journal-title":"Psychol Med"},{"issue":"3","key":"6772_CR27","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1093\/jmt\/thaa006","volume":"57","author":"C O\u2019Callaghan","year":"2020","unstructured":"O\u2019Callaghan C, Hubik DJ, Dwyer J, Williams M, Ross M (2020) Experience of music used with psychedelic therapy: a rapid review and implications. J Music Ther 57(3):282\u2013314. https:\/\/doi.org\/10.1093\/jmt\/thaa006","journal-title":"J Music Ther"},{"issue":"1","key":"6772_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12954-022-00662-0","volume":"19","author":"M Palmer","year":"2022","unstructured":"Palmer M, Maynard OM (2022) Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience. Harm Reduct J 19(1):81. https:\/\/doi.org\/10.1186\/s12954-022-00662-0","journal-title":"Harm Reduct J"},{"issue":"2","key":"6772_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1108\/DAT-03-2020-0016","volume":"1","author":"J Pestana","year":"2021","unstructured":"Pestana J, Beccaria F, Petrilli E (2021) Psychedelic substance use in the Reddit psychonaut community: a qualitative study on motives and modalities. Drugs Alcohol Today 1(2):112\u2013123. https:\/\/doi.org\/10.1108\/DAT-03-2020-0016","journal-title":"Drugs Alcohol Today"},{"issue":"5","key":"6772_CR30","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/0022167817711304","volume":"57","author":"J Phelps","year":"2017","unstructured":"Phelps J (2017) Developing guidelines and competencies for the training of psychedelic therapists. J Humanist Psychol 57(5):450\u2013487. https:\/\/doi.org\/10.1177\/0022167817711304","journal-title":"J Humanist Psychol"},{"issue":"2","key":"6772_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1177\/002204260203200207","volume":"32","author":"S Prepeliczay","year":"2002","unstructured":"Prepeliczay S (2002) Socio-cultural and psychological aspects of contemporary LSD use in Germany. J Drug Issues 32(2):431\u2013458. https:\/\/doi.org\/10.1177\/002204260203200207","journal-title":"J Drug Issues"},{"issue":"2","key":"6772_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","volume":"25","author":"M Renelli","year":"2020","unstructured":"Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A (2020) An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord 25(2):437\u2013444. https:\/\/doi.org\/10.1007\/s40519-018-0619-6","journal-title":"Eat Weight Disord"},{"key":"6772_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpsychires.2021.05.019","volume":"139","author":"AN Siegel","year":"2021","unstructured":"Siegel AN, Meshkat S, Benitah K, Lipsitz O, Gill H, Lui LMW, Teopiz KM, McIntyre RS, Rosenblat JD (2021) Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res 139:71\u201381. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.05.019","journal-title":"J Psychiatr Res"},{"issue":"2","key":"6772_CR34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/02791072.2022.2071134","volume":"55","author":"CM Soares","year":"2023","unstructured":"Soares CM, Leite A, Pinto M (2023) Self-care practices with psychedelics: a qualitative study of users\u2019 perspectives. J Psychoactive Drugs 55(2):159\u2013169. https:\/\/doi.org\/10.1080\/02791072.2022.2071134","journal-title":"J Psychoactive Drugs"},{"key":"6772_CR35","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41386-023-01609-0","volume":"48","author":"I Straumann","year":"2023","unstructured":"Straumann I, Ley L, Holze F, Becker AM, Klaiber A, Wey K, Duthaler U, Varghese N, Eckert A, Liechti ME (2023) Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants. Neuropsychopharmacol 48:1840\u20131848. https:\/\/doi.org\/10.1038\/s41386-023-01609-0","journal-title":"Neuropsychopharmacol"},{"issue":"5","key":"6772_CR36","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1177\/0022167817715966","volume":"57","author":"TC Swift","year":"2017","unstructured":"Swift TC, Belser AB, Agin-Liebes G, Devenot N, Terrana S, Friedman HL, Guss J, Bossis AP, Ross S (2017) Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanist Psychol 57(5):488\u2013519. https:\/\/doi.org\/10.1177\/0022167817715966","journal-title":"J Humanist Psychol"},{"key":"6772_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2024.02.004","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets B (2024) Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging. https:\/\/doi.org\/10.1016\/j.bpsc.2024.02.004","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"6772_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugpo.2017.02.017","volume":"44","author":"P Talin","year":"2017","unstructured":"Talin P, Sanabria E (2017) Ayahuasca\u2019s entwined efficacy: an ethnographic study of ritual healing from \u201caddiction.\u201d Int J Drug Policy 44:23\u201330. https:\/\/doi.org\/10.1016\/j.drugpo.2017.02.017","journal-title":"Int J Drug Policy"},{"key":"6772_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/002216782210813","author":"S Thal","year":"2022","unstructured":"Thal S, Engel LB, Bright SJ (2022) Presence, trust, and empathy: preferred characteristics of psychedelic carers. J Humanist Psychol. https:\/\/doi.org\/10.1177\/002216782210813","journal-title":"J Humanist Psychol"},{"issue":"1","key":"6772_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A, Holze F, Vandersmissen A, Mueller L, Duthaler U, Rudin D, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiat 13(1):172. https:\/\/doi.org\/10.1038\/s41398-023-02477-4","journal-title":"Transl Psychiat"},{"issue":"5","key":"6772_CR41","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski ND, Carhart-Harris R (2017) Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol 57(5):520\u2013564. https:\/\/doi.org\/10.1177\/0022167817709585","journal-title":"J Humanist Psychol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06772-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06772-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T06:44:54Z","timestamp":1753425894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06772-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6772"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06772-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice and were approved by the Ethics Committee of Northwest Switzerland (EKNZ) and Swiss Federal Office for Public Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MEL is a consultant for Mind Medicine, Inc. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}